[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Canadian College of Naturopathic Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100540947","phase-2-maitake-for-integrative-cancer-care-100540947",false,"NCT06323473","Maitake for Integrative Cancer Care","Maitake for Integrative Cancer Care: An Open Label, Uncontrolled Trial in People on Systemic Cancer Therapy","Maitake","Inclusion Criteria:\n\n1. Adults (≥18 years of age)\n2. Confirmed cancer diagnosis through biopsy or radiologic imaging\n3. Undergoing systemic treatment with either chemotherapy or CD4\u002F6 inhibitors\n4. Currently receiving cancer treatment in Ontario, Canada\n\nExclusion Criteria:\n\n1. Hematologic cancers\n2. Previously received any mushroom supplement within 6 months prior to enrolment\n3. Allergy to mushrooms or mushroom products\n4. Diagnosis of diabetes\n5. Currently taking hypoglycemic or anticoagulant medications\n6. Currently receiving immune checkpoint inhibitors\n7. Unable to attend in in-person visits in either Ottawa or Toronto\n8. Any reason which, under the discretion of the Qualified Investigator or delegate, would preclude the patient from participating","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Maitake is an edible mushroom that is used for both its nutritional and medicinal properties. Human and animal studies have shown Maitake may help improve immune function; however, its effectiveness in people with cancer is not clear. The investigators aim to measure if Maitake has any immunomodulatory effects when given alongside conventional systemic cancer therapy.",[27],"Cancer",[29,15,30,31,32,33],"Chemotherapy","Integrative Care","Integrative Medicine","Targeted Therapy","Neutrophil","RECRUITING","2026-01-22",{"date":37,"type":38},"2026-01-23","ACTUAL",{"date":40,"type":38},"2024-10-15",{"date":42,"type":21},"2026-05-15",{"name":44,"class":45},"The Canadian College of Naturopathic Medicine","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100504499","phase-2-adjunctive-intravenous-ascorbic-acid-for-advanced-non-small-cell-lung-cancer-100504499","NCT05849129","Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer","Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer: A Double Blind, Placebo Controlled, Phase II Randomized Controlled Trial","AIVAA","Inclusion Criteria:\n\n1. Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer\n2. Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy\n\nExclusion Criteria:\n\n1. ECOG status greater than 2\n2. Previously received IVC within 6 months prior to randomization\n3. Biochemical deficiency in G6PD\n4. Estimated Glomerular Filtration Rate (eGFR) less than 45 mL\u002Fmin\n5. Currently taking insulin or warfarin\n6. History of severe renal dysfunction or hemochromatosis\n7. Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization\n8. If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency\n9. Currently taking an investigational product or participation in an investigational study within the past 30 days\n10. Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating",{"count":56,"type":21},90,[24],"This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.",[60],"Lung Cancer",{"date":37,"type":38},{"date":63,"type":38},"2024-10-01",{"date":65,"type":21},"2031-10-01",{"name":44,"class":45},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":75,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":67},"100521796","phase-2-perinatal-depression--anxiety-pda-and-maternal-gut-microbiome-100521796","NCT06074250","Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome","Targeting Maternal Gut to Improve Mental Health Outcomes-- A Feasibility Pilot Clinical Trial","Inclusion Criteria\n\n* Women 18-43 years old\n* 12-35 weeks of gestation\n* Non-smoker\u002Falcohol\u002Frecreational drug user\n* Financially stable\n* Clinical diagnosis of lifetime depression\u002Fanxiety or PDA but currently well\n* English speaking\n\nExclusion Criteria:\n\n* Body Mass Index (BMI)≥30\n* Low income (unable to afford basic daily needs (i.e., shelter, food, etc.)\n* Diagnosis with other major mental health disorders (Bipolar, Psychosis, Addiction, Schizophrenia);\n* Diagnosis with other severe medical conditions (i.e. epilepsy, neurological disorders, etc.)\n* Allergies to fish oils\u002Fingredients in supplements\n* Conditions that require repeated\u002Fchronic antibiotic usage\n* Having a child with significant mental\u002Fphysical disability\n* Single mothers without any kind of family support,\n* Cigarette, alcohol and recreational drug users\n* Women unwilling to switch to study product(s)\n* Multiparous women with young children (i.e. one or more children less than 4 years of age at the time of delivery)\n* Non-English Readers\u002FSpeakers","FEMALE","43 Years",{"count":78,"type":21},100,[24,80],"PHASE3","Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies. The adverse outcomes extend beyond maternal well-being to long-term deficits in children and families. The gut-brain axis is a newly recognized key player in mental health disorders. Specifically, the microbial composition of the gut along with their metabolites are directly involved in disease onset and course. Recent clinical studies have identified diet as the most powerful environmental factor in manipulating gut microbiome. Given vulnerability and resistance of pregnant women to pharmacotherapy, particularly in those with a predisposition to mood disorders, as well as pregnant women's high motivation and commitment to improving gestational diet, a dietary\u002Fsupplemental intervention to 'optimize' gut microbiome, is a favored approach in disease management. The study investigators aim to exploit microbial responsiveness to diet together with this maternal motivation, to alter the risk and severity of a universal public health concern that has dire and long-term consequences for new moms and their children.\n\nThe investigators of this trial, will first study the challenges in pursuing a study aimed at changing the microbiome of pregnant women with a history of mood disorders. Pregnant women in their second trimester will be recruited. Each will be assigned or randomized to one of four groups that will use a combination of diet, supplementation with probiotics, fish oil or no intervention. Each participant will meet with the study team virtually every 3 months until 1 year after delivery. At each study visit participants will be required to complete some questionnaires about their food intake, mood, and other health related measures and will provide a stool sample using the stool collection kits provided.\n\nThe findings from this study will help strategize for a larger study that will allow for comparison of the effects of diet, and\u002For supplementation with Omega-3 Fatty Acids (O3FA) and probiotics on the microbiome and the onset and severity of PDA.",[83,84],"Perinatal Depression","PerinatalAnxiety",[86,87,88,89,90,91,92,93],"Gut Microbiome","Gut-Brain Axis","Diet","Omega 3 Fatty acids","Probiotics","Fish Oil","Mental Health disorders","Perinatal Depression and anxiety","2024-08-22",{"date":96,"type":38},"2024-08-27",{"date":98,"type":38},"2024-08-15",{"date":100,"type":21},"2028-03",{"name":44,"class":45},""]